Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP4 | P12644 | 7/20 | 0.70 |
| ▸ | ACVR1 | Q04771 | 14/20 | 0.61 |
| ▸ | ACVR1B | P36896 | 13/20 | 0.61 |
| ▸ | ACVRL1 | P37023 | 12/20 | 0.61 |
| ▸ | BMPR1B | O00238 | 11/20 | 0.61 |
| ▸ | BMPR1A | P36894 | 11/20 | 0.61 |
| ▸ | KDR | P35968 | 6/20 | 0.61 |
| ▸ | TGFBR1 | P36897 | 5/20 | 0.61 |
| ▸ | PRKAB1 | Q9Y478 | 5/20 | 0.61 |
| ▸ | TGFBR2 | P37173 | 4/20 | 0.61 |
| ▸ | BMPR2 | Q13873 | 3/20 | 0.56 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.55 |
| ▸ | ACVR2A | P27037 | 1/20 | 0.55 |
| ▸ | ACVR2B | Q13705 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30074621 | 1.00 | BMP4 (0.70) | BMP4ACVR1ACVR1BACVRL1BMPR1B | |
| SCHEMBL12779978 | 0.86 | BMP4 (0.82) | BMP4ACVR1ACVR1BACVRL1BMPR1B | |
| SCHEMBL11953449 | 0.83 | BMP4 (1.00) | BMP4ACVR1ACVR1BACVRL1BMPR1B | |
| SCHEMBL16112689 | 0.80 | BMP4 (0.68) | BMP4ACVR1ACVR1BACVRL1BMPR1B | |
| SCHEMBL16112768 | 0.80 | ACVR1 (0.58) | BMP4ACVR1ACVR1BACVRL1BMPR1B | |
| SCHEMBL16112179 | 0.80 | BMP4 (0.80) | BMP4ACVR1ACVR1BACVRL1BMPR1B | |
| SCHEMBL30665011 | 0.79 | BMP4 (1.00) | BMP4ACVR1ACVR1BACVRL1BMPR1B | |
| SCHEMBL11953871 | 0.79 | BMP4 (1.00) | BMP4ACVR1ACVR1BACVRL1BMPR1B | |
| SCHEMBL17531593 | 0.79 | BMP4 (0.82) | BMP4ACVR1ACVR1BACVRL1BMPR1B | |
| SCHEMBL11953445 | 0.79 | BMP4 (1.00) | BMP4ACVR1ACVR1BACVRL1BMPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100178307-A1 | TRANSDERMAL ANTI-DEMENTIA ACTIVE AGENT FORMULATIONS AND METHODS FOR USING THE SAME | TEIKOKU PHARMA USA INC. | 2010-07-15 | — | — | US | claimed |
| US-20070259028-A1 | used as plaster on skin; comprises adherent layer, intermediate membrane, and drug reservoir layer sequentially from skin side, wherein drug reservoir layer comprises an antidementia drug, an aminated polymer, a polyhydric alcohol, and carboxylic acid esters | TEIKOKU SEIYAKU CO., LTD. (JP) | 2007-11-08 | — | — | US | claimed |
| EP-4374928-A2 | NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING | The Brigham And Women's Hospital Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| EP-3615538-B1 | NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING | BRIGHAM & WOMENS HOSPITAL INC (US) | 2024-02-07 | — | — | EP | disclosed |
| US-11654147-B2 | ALK2 inhibitors and methods for inhibiting BMP signaling | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| CN-111164083-B | Novel ALK2 inhibitors and methods for inhibiting BMP signaling | 布里格姆妇女医院股份有限公司 | 2023-01-10 | — | — | CN | disclosed |
| US-20230000869-A1 | NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2023-01-05 | — | — | US | disclosed |
| US-11026947-B2 | ALK2 inhibitors and methods for inhibiting BMP signaling | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-20200179389-A1 | NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-06-11 | — | — | US | disclosed |
| CN-111164083-A | Novel ALK2 inhibitors and methods for inhibiting BMP signaling | 布里格姆妇女医院股份有限公司 | 2020-05-15 | — | — | CN | disclosed |
| US-10017516-B2 | BMP inhibitors and methods of use thereof | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20110053930-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053930-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053930-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| EP-2265603-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | The General Hospital Corporation (US) | 2010-12-29 | — | — | EP | disclosed |
| US-7858114-B2 | used as plaster on skin; comprises adherent layer, intermediate membrane, and drug reservoir layer sequentially from skin side, wherein drug reservoir layer comprises an antidementia drug, an aminated polymer, a polyhydric alcohol, and carboxylic acid esters | TEIKOKU SEIYAKU CO., LTD. (JP) | 2010-12-28 | — | — | US | disclosed |
| US-20100178307-A1 | TRANSDERMAL ANTI-DEMENTIA ACTIVE AGENT FORMULATIONS AND METHODS FOR USING THE SAME | TEIKOKU PHARMA USA INC. | 2010-07-15 | — | — | US | disclosed |
| WO-2009114180-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | THE GENERAL HOSPITAL CORPORATION (US) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009114180-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | THE GENERAL HOSPITAL CORPORATION (US) | 2009-09-17 | — | — | WO | disclosed |
| US-20070259028-A1 | used as plaster on skin; comprises adherent layer, intermediate membrane, and drug reservoir layer sequentially from skin side, wherein drug reservoir layer comprises an antidementia drug, an aminated polymer, a polyhydric alcohol, and carboxylic acid esters | TEIKOKU SEIYAKU CO., LTD. (JP) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200179389-A1 | NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING | BMPR2, BMP1, BMP2K | BMP4 13/4885ACVR1 6/4885ACVR1B 15/4885 |
| US-20110053930-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | BMP1, BMP2K, BMP2 | BMP4 4/4885ACVR1 9/4885ACVR1B 11/4885 |
| US-20230000869-A1 | NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING | BMPR2, BMP1, BMP2K | BMP4 13/4885ACVR1 6/4885ACVR1B 15/4885 |
| US-11654147-B2 | ALK2 inhibitors and methods for inhibiting BMP signaling | BMPR2, BMP1, BMP2K | BMP4 12/4885ACVR1 6/4885ACVR1B 15/4885 |
| US-11026947-B2 | ALK2 inhibitors and methods for inhibiting BMP signaling | BMPR2, BMP1, BMP2K | BMP4 12/4885ACVR1 6/4885ACVR1B 15/4885 |
| US-10017516-B2 | BMP inhibitors and methods of use thereof | BMP1, BMPR2, BMP2 | BMP4 6/4885ACVR1 13/4885ACVR1B 16/4885 |
| US-20100178307-A1 | TRANSDERMAL ANTI-DEMENTIA ACTIVE AGENT FORMULATIONS AND METHODS FOR USING THE SAME | ACHE, CHAT, GAP43 | BMP4 3030/4885ACVR1 4861/4885ACVR1B 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.